Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Healthtrust
Moodys
QuintilesIMS
Julphar
Chubb
McKinsey
Boehringer Ingelheim
Fuji

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021004

« Back to Dashboard

NDA 021004 describes EPIVIR-HBV, which is a drug marketed by Glaxosmithkline and is included in two NDAs. It is available from three suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the EPIVIR-HBV profile page.

The generic ingredient in EPIVIR-HBV is lamivudine. There are twenty-eight drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the lamivudine profile page.
Summary for 021004
Tradename:EPIVIR-HBV
Applicant:Glaxosmithkline
Ingredient:lamivudine
Patents:1
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details
Pharmacology for NDA: 021004
Medical Subject Heading (MeSH) Categories for 021004
Suppliers and Packaging for NDA: 021004
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EPIVIR-HBV lamivudine SOLUTION;ORAL 021004 NDA GlaxoSmithKline LLC 0173-0663 N 0173-0663-00

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;ORALStrength5MG/ML
Approval Date:Dec 8, 1998TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Sep 20, 2018Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 021004

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline EPIVIR-HBV lamivudine SOLUTION;ORAL 021004-001 Dec 8, 1998 ➤ Sign Up ➤ Sign Up
Glaxosmithkline EPIVIR-HBV lamivudine SOLUTION;ORAL 021004-001 Dec 8, 1998 ➤ Sign Up ➤ Sign Up
Glaxosmithkline EPIVIR-HBV lamivudine SOLUTION;ORAL 021004-001 Dec 8, 1998 ➤ Sign Up ➤ Sign Up
Glaxosmithkline EPIVIR-HBV lamivudine SOLUTION;ORAL 021004-001 Dec 8, 1998 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
UBS
Johnson and Johnson
Harvard Business School
Colorcon
US Department of Justice
McKesson
Queensland Health
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.